Cullinan Therapeutics, Inc.

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies targeting autoimmune diseases and cancer. The company's lead program, zipalertinib, is a small molecule drug candidate in Phase 3 testing for non-small cell lung cancer, developed under a co-development agreement with Taiho Pharmaceutical Co., Ltd. The pipeline also includes CLN-978, a T cell engager in development for systemic lupus erythematosus and rheumatoid arthritis, alongside earlier-stage candidates CLN-619 (a monoclonal antibody for solid tumors and multiple myeloma), CLN-049 (a bispecific antibody for acute myeloid leukemia and myelodysplastic syndrome), and CLN-617 (a fusion protein for solid tumors), all in Phase 1 trials.

The company has established a collaboration with Adimab, LLC for antibody discovery and optimization. As a clinical-stage biotech firm, Cullinan does not generate product revenues. The company was incorporated in Delaware in 2016 and operates from its headquarters in Cambridge, Massachusetts, with a team of 111 full-time employees. Cullinan changed its name from Cullinan Oncology in April 2024 to reflect its expanded focus beyond oncology into autoimmune disease indications.